B. Riley Equities Analysts Raise Earnings Estimates for CymaBay Therapeutics Inc (NASDAQ:CBAY)

CymaBay Therapeutics Inc (NASDAQ:CBAY) – Equities research analysts at B. Riley raised their Q3 2019 earnings per share estimates for shares of CymaBay Therapeutics in a research note issued on Monday, June 10th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings per share of ($0.45) for the quarter, up from their prior forecast of ($0.46). B. Riley currently has a “Hold” rating and a $11.00 target price on the stock. B. Riley also issued estimates for CymaBay Therapeutics’ Q4 2019 earnings at ($0.50) EPS, FY2019 earnings at ($1.74) EPS, FY2020 earnings at ($2.03) EPS, FY2021 earnings at ($2.67) EPS, FY2022 earnings at ($1.57) EPS and FY2023 earnings at ($1.29) EPS.

A number of other analysts have also recently issued reports on the company. Piper Jaffray Companies set a $30.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a report on Friday, March 1st. Roth Capital reissued a “buy” rating on shares of CymaBay Therapeutics in a report on Tuesday, February 19th. Oppenheimer set a $18.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a report on Friday, February 15th. Citigroup began coverage on CymaBay Therapeutics in a report on Tuesday, May 14th. They set a “buy” rating and a $21.00 price objective on the stock. Finally, BidaskClub raised CymaBay Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $15.44.



Shares of CBAY opened at $6.17 on Wednesday. The stock has a market cap of $423.84 million, a P/E ratio of -4.90 and a beta of 1.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.66 and a current ratio of 18.66. CymaBay Therapeutics has a 52-week low of $4.82 and a 52-week high of $15.00.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

Several large investors have recently added to or reduced their stakes in CBAY. Advisor Group Inc. raised its holdings in shares of CymaBay Therapeutics by 281.9% in the 1st quarter. Advisor Group Inc. now owns 2,601 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,920 shares in the last quarter. Meeder Asset Management Inc. raised its holdings in shares of CymaBay Therapeutics by 307.3% in the 1st quarter. Meeder Asset Management Inc. now owns 2,839 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,142 shares in the last quarter. Pearl River Capital LLC bought a new position in shares of CymaBay Therapeutics during the 4th quarter valued at about $74,000. D. E. Shaw & Co. Inc. bought a new position in shares of CymaBay Therapeutics during the 4th quarter valued at about $82,000. Finally, PNC Financial Services Group Inc. increased its position in shares of CymaBay Therapeutics by 23.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,460 shares during the last quarter. 99.53% of the stock is currently owned by hedge funds and other institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Article: Book Value Per Share – BVPS

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

B. Riley Equities Analysts Raise Earnings Estimates for CymaBay Therapeutics Inc (NASDAQ:CBAY)

CymaBay Therapeutics Inc (NASDAQ:CBAY) – Equities research analysts at B. Riley raised their Q3 2019 earnings per share estimates for shares of CymaBay Therapeutics in a research note issued on Monday, June 10th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings per share of ($0.45) for the quarter, up from their prior forecast of ($0.46). B. Riley currently has a “Hold” rating and a $11.00 target price on the stock. B. Riley also issued estimates for CymaBay Therapeutics’ Q4 2019 earnings at ($0.50) EPS, FY2019 earnings at ($1.74) EPS, FY2020 earnings at ($2.03) EPS, FY2021 earnings at ($2.67) EPS, FY2022 earnings at ($1.57) EPS and FY2023 earnings at ($1.29) EPS.

A number of other analysts have also recently issued reports on the company. Piper Jaffray Companies set a $30.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a report on Friday, March 1st. Roth Capital reissued a “buy” rating on shares of CymaBay Therapeutics in a report on Tuesday, February 19th. Oppenheimer set a $18.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a report on Friday, February 15th. Citigroup began coverage on CymaBay Therapeutics in a report on Tuesday, May 14th. They set a “buy” rating and a $21.00 price objective on the stock. Finally, BidaskClub raised CymaBay Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $15.44.



Shares of CBAY opened at $6.17 on Wednesday. The stock has a market cap of $423.84 million, a P/E ratio of -4.90 and a beta of 1.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.66 and a current ratio of 18.66. CymaBay Therapeutics has a 52-week low of $4.82 and a 52-week high of $15.00.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

Several large investors have recently added to or reduced their stakes in CBAY. Advisor Group Inc. raised its holdings in shares of CymaBay Therapeutics by 281.9% in the 1st quarter. Advisor Group Inc. now owns 2,601 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,920 shares in the last quarter. Meeder Asset Management Inc. raised its holdings in shares of CymaBay Therapeutics by 307.3% in the 1st quarter. Meeder Asset Management Inc. now owns 2,839 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,142 shares in the last quarter. Pearl River Capital LLC bought a new position in shares of CymaBay Therapeutics during the 4th quarter valued at about $74,000. D. E. Shaw & Co. Inc. bought a new position in shares of CymaBay Therapeutics during the 4th quarter valued at about $82,000. Finally, PNC Financial Services Group Inc. increased its position in shares of CymaBay Therapeutics by 23.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,460 shares during the last quarter. 99.53% of the stock is currently owned by hedge funds and other institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Article: Book Value Per Share – BVPS

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.